

## Prediction and diagnosis of renal cell carcinoma using nuclear magnetic resonance-based serum metabolomics and self-organizing maps

### Supplementary Materials

**Table S1: Assignment of metabolites in <sup>1</sup>H NMR spectra from human serum samples**

No.	Compound	ppm	Assignment	Multiplicity
1	LDL/VLDL	0.84–0.91, 1.22–1.31	CH <sub>3</sub> (CH <sub>2</sub> ) <sub>n</sub> /CH <sub>3</sub> CH <sub>2</sub> CH <sub>2</sub> C =, (CH <sub>2</sub> ) <sub>n</sub> /CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> CO	m, m
2	isoleucine	0.92–0.93, 1.00–1.02	d-CH <sub>3</sub> , b-CH <sub>3</sub>	t, d
3	leucine	0.94–0.97	d-CH <sub>3</sub>	d, d
4	valine	0.98–1.00, 1.03–1.05	CH <sub>3</sub> , CH <sub>3</sub>	d, d
5	lactate	1.32–1.35, 4.10–4.15	CH <sub>3</sub> , CH	d, q
6	alanine	1.47–1.50	CH <sub>3</sub>	d
7	lipids + NAC	1.98–2.10	-	m
8	glutamine	2.42–2.48	half g-CH <sub>2</sub>	m
9	creatine	3.04–3.05	CH <sub>3</sub>	s
10	choline	3.20–3.22	N(CH <sub>3</sub> ) <sub>3</sub>	s
11	TMAO	3.26–3.27	N(CH <sub>3</sub> ) <sub>3</sub>	s
12	taurine	3.40–3.42	CH <sub>2</sub>	t
13	sugars + AAs	3.48–3.88	various	m
14	β-glucose	4.63–4.67	CH	d
15	α-glucose	5.22–5.25	CH	d
16	poly-UFA	5.26–5.36	CH = CHCH <sub>2</sub> CH = CH, = CHCH <sub>2</sub> CH <sub>2</sub>	m

Abbreviations: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; LDL, low density lipid; VLDL, very low density lipid; NAC, *N*-acetyl signals from α<sub>1</sub>-acid glycoproteins; TMAO, *N*-oxide trimethylamine; AA, amino acid.